Takeda submits Japanese NDA for rasagiline to treat PD

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted an NDA in Japan for Azilect rasagiline mesylate (TVP-1012) to treat Parkinson’s disease (PD). The product is an irreversible selective inhibitor of monoamine oxidase B (MAO-B).

In 2014, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) granted Takeda exclusive, Japanese rights to develop and commercialize rasagiline (see BioCentury, May 5, 2014)...